您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Batabulin sodium
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Batabulin sodium
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Batabulin sodium图片
规格:98%
分子量:393.24
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议

产品介绍
Batabulinsodium(T138067sodium)是一种抗肿瘤剂,可与β-微管蛋白同种型的子集共价且选择性地结合,从而破坏微管(microtubule)聚合。Batabulinsodium影响细胞形态并导致细胞周期停滞,最终诱导凋亡性细胞死亡。
货号:ajcx30232
CAS:195533-98-3
分子式:C13H6F6NNaO3S
分子量:393.24
溶解度:DMSO: 125 mg/mL (317.87 mM)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Batabulin sodium (T138067 sodium) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin sodium affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death[1].

Batabulin (T138067; 30-300 nM; 24 hours; MCF7 cells) treatment shows approximately 25-30% tetraploid (4n) DNA content in cells, indicating an arrest at the G2/M cell-cycle boundary[1].Batabulin (T138067; 30-300 nM; 24-48 hours; MCF7 cells) treatment shows 25-30% apoptosis. After a 48-hr exposure to 100 nM Batabulin, approximately 50-80% of the cell population is undergoing apoptosis[1].Batabulin (T138067) binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Covalent modification occurs at a conserved Cys-239 shared by the β1, β2, and β4 tubulin isotypes. Cells exposed to Batabulin become altered in shape, indicating a collapse of the cytoskeleton, and show an increase in chromosomal ploidy[1]. Cell Cycle Analysis[1] Cell Line: MCF7 cells

Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors[1]. Animal Model: Male athymic nude mice (nu/nu) (6-8 week-old, 20-25 g) injected withCCRF-CEM cells[1]

[1]. Shan B, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5686-91.